Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2018-08-17 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
第一期员工持股计划管理办法
Governance Information Classification · 95% confidence The document is titled as the "First Employee Stock Ownership Plan Management Measures" of 福安药业（集团）股份有限公司. It details the rules, procedures, rights, and obligations related to the employee stock ownership plan, including participation criteria, funding sources, stock acquisition, management structure, meetings, voting, and termination. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is a detailed governance document outlining internal rules and management practices for the employee stock ownership plan. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-08-17 Chinese
第一期员工持股计划（草案修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "福安药业第一期员工持股计划（草案修订稿）" which translates to "Fuan Pharmaceutical First Employee Stock Ownership Plan (Draft Revision)". It is a detailed plan document outlining the purpose, principles, participants, funding sources, stock sources, duration, management, rights and obligations of participants, and procedures related to an employee stock ownership plan. The document includes references to relevant laws and regulations, detailed governance structures, voting procedures, and authorization by the shareholders' meeting and board of directors. It is not a financial report, earnings release, or regulatory announcement but a comprehensive plan document related to employee stock ownership. This type of document fits best under the category of Capital/Financing Update (CAP) because it relates to the company's capital structure and financing activities through an employee stock ownership plan. The document length (over 14,000 characters) and detailed content confirm it is the plan itself, not just an announcement or summary. Therefore, the classification is CAP with high confidence.
2018-08-17 Chinese
第三届监事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 福安药业 (Fuan Pharmaceutical Group) regarding the approval of amendments to the company's first employee stock ownership plan and its management measures. It includes details about the meeting, voting results, and compliance with relevant laws and regulations. The document does not contain financial statements, audit opinions, or detailed financial data. It is not an annual or interim report, earnings release, or investor presentation. It is also not a regulatory certification or a report publication announcement. The content focuses on board-level decisions and governance related to employee stock plans, which fits best under Board/Management Information (MANG). The document length is short (1033 characters), and it is a formal announcement of board resolutions rather than a full report or presentation.
2018-08-17 Chinese
关于控股股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a major shareholder of the company. It details the number of shares released from pledge, the dates, and the proportion of shares involved. There is no financial report, earnings data, management discussion, or regulatory certification. The content focuses on share pledge status and changes in shareholding security, which fits the category of Major Shareholding Notification (MRQ). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is MRQ with high confidence.
2018-08-17 Chinese
关于控股股东的一致行动人部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder and their related party. It details the number of shares pledged, the dates, the pledgee, and the proportion of shares pledged relative to total holdings and company shares. There is no indication of financial statements, management discussion, or regulatory certifications. The document is a specific announcement about a shareholder's share pledge, which fits the category of Capital/Financing Update (CAP) as it relates to changes in capital structure or financing activities through share pledging.
2018-08-16 Chinese
关于收到药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving a drug registration approval from the national drug regulatory authority. It contains no financial data, no detailed report, and is primarily an official notification about regulatory approval. The document length is only 1018 characters, which is quite short and fits the pattern of an announcement rather than a full report. There is no indication of financial results, management discussion, or other report content. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-08-13 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.